Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

VERY BAD NEWS: The Timeline & Milestones have changed dramatically since the last corporate presentation.

Management previously stated there would be expected data from IBD study in Q3 2020 & expected data from NASH and CKD study in 1Q 2021. Data reporting has been pushed back by more than a year for each study. Your money (what's left since the split/forthcoming mass dilution) will be dormant/door mat for the next 2 years. That is a dramatic difference and falls right in line with the Bullrun theme of never getting to real world monetization. I'm not sticking around 2 more years to cheer for these guys. There's nothing to cheer. There isn't a RUO breathalyzer anywhere in plain sight (never has been), and given the BS rollout of Camp Cannabix UBC technology, I remain convinced the FAIMS technology is nowhere near monetization, if ever. Surely, the timelines and stories will continue to morph themselves into one slow moving train wreck after the other.

That FN Kal & Henchmen did us in again!

www.sedar.com/GetFile.do?lang=EN&docClass=9&issuerNo=00037722&issuerType=03&projectNo=02937735&docId=4599375

Short Form Prospectus - Page 24

In the fourth quarter of 2019, the Company expects to begin cGMP synthesis of NP-135 and initiate additional pre-clinical research. In the first quarter of 2020, the Company expects to seek approval for the IBD or IPF trial in Australia, complete its idiopathic pulmonary fibrosis research, complete pre-clinical studies and publish related research papers with respect to all the Company’s animal in vivo studies and begin the IBD or IPF trial. In
the second quarter of 2020, the Company expects to complete the cGMP synthesis of NP-135 and submit for ethics evaluation the NASH NP-135 and the NP-135 CKD study in Australia, New Zealand and the Ukraine, assuming completion of the Maximum Offering. In the third quarter of 2020, the Company expects to begin the NASH NP135 and the NP-135 CKD study. The Company anticipates receiving data from the IBD or IPF phase II study by the fourth quarter of 2021 and from the NASH and CKD studies by the first quarter of 2022.

PEACE & GL2ALL ~ AMG GONE!